LLY
Eli Lilly and Company
LLY has the edge over STOK overall, supported by stronger fundamentals and stronger modeled upside.
STOK
Stoke Therapeutics, Inc.
STOK trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
STOK Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
STOK's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
STOK PE Valuation
STOK has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
STOK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect STOK's losses to grow, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over STOK on earnings quality, reporting a profit while its opponent remains loss making.
STOK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.77 | -639% |
| Q2 2026 | -$3.34 | -480% |
| Q1 2026 | -$2.81 | -443% |
| Q4 2025 | -$0.12 | +$1.53 |
| Q3 2025 | $0.70 | +$2.81 |
| Q2 2025 | $0.88 | +$3.07 |
| Q1 2025 | $0.82 | +$3.24 |
| Q4 2024 | -$1.65 | +$0.73 |
STOK has swung to a loss: it lost $3.77 per share over the past year, after a profit the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over STOK on profitability, with a higher operating margin.
STOK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.3M | +5.9% |
| Q2 2026 | $9.3M | -33% |
| Q1 2026 | $6.2M | -96% |
| Q4 2025 | $1.4M | -94% |
| Q3 2025 | $10.6M | +117% |
| Q2 2025 | $13.8M | +186% |
| Q1 2025 | $158.6M | +3661% |
| Q4 2024 | $22.6M | +707% |
STOK's revenue is recovering but still below its 2025 peak: $11M last quarter, up 5.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -687% | -282 points |
| Q2 2026 | -702% | -504 points |
| Q1 2026 | -858% | -928 points |
| Q4 2025 | -4382% | -4322 points |
| Q3 2025 | -405% | +208 points |
| Q2 2025 | -198% | +410 points |
| Q1 2025 | 70% | +743 points |
| Q4 2024 | -60% | +996 points |
STOK's operating margin was −687% last quarter, down 282 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over STOK on cash generation, producing positive trailing cash flow while its opponent burns cash.
STOK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$65.5M | -$35M |
| Q2 2026 | -$58.6M | -$33M |
| Q1 2026 | -$60.9M | -146% |
| Q4 2025 | -$30.7M | -$7.5M |
| Q3 2025 | -$30.5M | -$8.8M |
| Q2 2025 | -$25.6M | -$8.1M |
| Q1 2025 | $131.7M | +$156.3M |
| Q4 2024 | -$23.2M | -$2.4M |
STOK has burned cash in almost every quarter: −$216M over the past year, against $52M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over STOK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
STOK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.6% | +2.3M shares |
| 1 year | +17% | +9.8M shares |
| 3 years | +54% | +24.1M shares |
| 5 years | +86% | +31.6M shares |
| Available history | +108% | +35.5M shares |
STOK has 68M diluted shares, up 17% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2023 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
STOK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -2.9x | Net Cash |
| Q2 2025 | -2.4x | Net Cash |
| Q1 2025 | -6.8x | Net Cash |
STOK has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
STOK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.8 | Neutral |
| Stochastic | 36.1 | Neutral |
STOK's weekly RSI is 43 (neutral) and its Stochastic is 36 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
STOK PE vs Healthcare Sector
| Metric | STOK | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
STOK has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over STOK on trend strength, trading above more of its moving averages.
STOK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $25.4 | 3.1% above |
| 20 week MA | $28.5 | 8% below |
| 50 week MA | $30.7 | 15% below |
| 100 week MA | $22.9 | 14% above |
| 200 week MA | $16.2 | 61% above |
STOK's trend is mixed: it's above three of its five weekly moving averages, and 61% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over STOK on returns for 2026, with the stronger performance.
STOK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.6 | $58.3 | +119% |
| 2021 | $58.3 | $21.6 | -63% |
| 2022 | $21.6 | $8.30 | -62% |
| 2023 | $8.30 | $5.26 | -37% |
| 2024 | $5.26 | $11.1 | +110% |
| 2025 | $11.1 | $31.9 | +189% |
| 2026 YTD | $31.9 | $26.2 | -18% |
STOK's yearly returns have swung widely, from +189% in 2025 to −63% in 2021. It's down 18% so far in 2026.